Pressure on Abbvie's pipeline grows
Abbvie will need more than Skyrizi and upadacitinib to fill a Humira-shaped hole, and there are a few early-stage candidates it reckons could fit the bill.
Mustang and the bubble boy bubble
The value of Mustang Bio has tripled on data on its immune deficiency gene therapy. But investors might be too keen – and also too late.
Boehringer pushes pipeline progress
The notoriously secretive German pharma company Boehringer Ingelheim has made much of a new drive towards transparency, but there are still things it would rather keep to…
Wave crashes again – this time on toxicity concerns
A run of bad news leaves investors questioning Wave Life Sciences’ ability to deliver on its promises.
US shutdown dampens first-quarter flotations
Biopharma IPOs dipped in the opening months of 2019, but numbers look fairly healthy despite January's US government closure.
Lukewarm data for Second Sight
Second Sight’s second product might lead the company to second place in the market.
AACR 2019 – Vitrakvi relapse findings justify Bayer’s interest
The Vitrakvi follow-on LOXO-195 yields results backing both the rationale behind its development and Bayer’s decision to take on full rights.
The bubble bursts for Proteostasis
Investors had previously given Proteostasis the benefit of the doubt, but the company’s latest cystic fibrosis update leaves little hope to cling to.
Axovant reaps the rewards from its gene therapy refocus
Axovant is the latest company to benefit from excitement over gene therapy data in small numbers of patients.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.